Form 4 for APRE Aprea Therapeutics, Inc.
Accepted 2023-03-13 00:00:00 ET · period of report 2022-08-23 · accession 0001104659-23-031882 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-13 | 2022-08-23 | APRE | Gilad Oren | Pres, CEO, Dir | C - Cnv Deriv | $0.00 | +6.05M | 6.38M | +1,830% | $0 |
| D | 2023-03-13 | 2023-03-09 | APRE | Gilad Oren | Pres, CEO, Dir | A - Grant | $0.00 | +4,000 | 322.8K | +1% | $0 |
| D | 2023-03-13 | 2023-03-09 | APRE | Gilad Oren | Pres, CEO, Dir | A - Grant | $0.00 | +16.0K | 16.0K | New | $0 |
| D | 2023-03-13 | 2022-08-23 | APRE | Gilad Oren | Pres, CEO, Dir | C - Cnv Deriv | $0.00 | -604.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-23 | C | A | 6,045,100 | $0.00 | 6,375,414 | D | — | — | (F2) Each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of Common Stock any time at the option of the holder thereof, subject to certain limitations. On August 23, 2022, the Reporting Person converted 604,510 shares of Series A Non-Voting Convertible Preferred Stock into 6,045,100 shares of Common Stock. |
| 2 | Common | Common Stock | 2023-03-09 | A | A | 4,000 | $0.00 | 322,770 | D | — | — | (F1) These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock ("Common Stock") in three (3) equal annual installments beginning on March 9, 2024 until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. (F4) Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023. |
| 3 | Derivative | Stock Options (Right to Buy) | 2023-03-09 | A | A | 16,000 | $0.00 | 16,000 | D | $5.08 · — to 2033-03-09 | 16,000 Common Stock | (F3) Twenty-five percent of these options vest on March 9, 2024, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |
| 4 | Derivative | Series A Non-Voting Convertible Preferred Stock | 2022-08-23 | C | D | 604,510 | $0.00 | 0 | D | — · — to — | 6,045,100 Common Stock | (F2) Each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of Common Stock any time at the option of the holder thereof, subject to certain limitations. On August 23, 2022, the Reporting Person converted 604,510 shares of Series A Non-Voting Convertible Preferred Stock into 6,045,100 shares of Common Stock. |